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Research in context 
Evidence before this study 
Direct oral anticoagulants (DOAC) are being increasingly used for all indications for 
anticoagulation. One of the main complications with DOAC use is gastrointestinal 
(GI) bleeding. There is conflicting evidence on the risk of GI bleeding with DOACs 
compared to warfarin and low molecular weight heparin (LMWH). 
Added value of this study 
This is the largest study to date to analyse the effect of GI bleeding with DOACs and 
the first network meta-analysis encompassing all indications for anticoagulation. We 
have shown that there is no difference in association between each class of DOAC, 
warfarin and low molecular weight heparin and major GI bleeding. Factor Xa 
inhibitors may be superior to dabigatran and warfarin for all severities of GI bleeding. 
Implications of all the available evidence 
Projected use of DOACs is likely to continue to increase for all indications due to the 
ease of dosing and lack of monitoring required. The evidence supports the continued 
use of DOACs from a GI bleeding perspective. 
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Abstract 
Background ± Direct oral anticoagulants (DOAC) are being increasingly used for a 
wide range of indications. There is conflicting data on the risk of major gastrointestinal 
(GI) bleeding with these medications. The aim of this study was to compare the risk of 
GI bleeding with DOAC, warfarin and low molecular weight heparin (LMWH).  
Methods - We performed a comprehensive search of the available evidence to April 
2016. Prospective and retrospective studies were included reporting on the risk of GI 
bleeding when using a DOAC compared to warfarin or LMWH for all indications. The 
primary outcome of interest was the incidence of major GI bleeding with all GI bleeding 
as a secondary outcome. We performed a Bayesian network meta-analysis to produce 
incidence rate ratios (IRR) with 95% credible intervals (CrI). 
Findings - We included 31 articles reporting on 287, 692 patients exposed to 230, 
090 years of anticoagulant medication in our primary analysis. We found no difference 
in the risk of major GI bleeding when comparing DOAC medications with warfarin and 
LMWH. This result was sustained on pre-specified sensitivity analyses to test the 
robustness of the result. When analysing all severities of GI bleeding, we found a 
reduction in risk when comparing factor Xa inhibitors with warfarin, IRR 0. 0.25 (95% 
CrI 0.07 ± 0.76) and thrombin inhibitors, IRR 0.24 (95% CrI (0.07 ± 0.77) respectively. 
Interpretation ± We have shown no association between the use of DOAC 
medications and the risk of major GI bleeding compared to warfarin and LMWH. This 
supports the continued use of DOAC medications from a GI bleeding perspective.  
Funding ± Dr Burr is in receipt of a fellowship from the Leeds Teaching Hospitals 
Charitable Foundation.    
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Introduction 
The direct oral anticoagulants (DOACs), previously known as novel oral 
anticoagulants and non-vitamin k oral anticoagulants(1), are a group of medications 
that are increasingly being used for the treatment and prevention of thromboembolism. 
There are several approved medications which comprise inhibitors of thrombin 
(dabigatran etexilate) and factor Xa (rivaroxaban, apixaban and edoxaban). DOACs 
have shown non-inferiority when compared to the established treatments for stroke 
prophylaxis in atrial fibrillation (AF)(2) and prophylaxis against and treatment of venous 
thromboembolism (VTE).(3) The DOACs are being rapidly incorporated into clinical 
practice and DOAC prescriptions were similar to warfarin for AF anticoagulation in 
2014 in the USA.(4) 
Bleeding is the main complication of anticoagulation therapy. Annual rates of major 
bleeding in patients prescribed warfarin has been shown to be as high as 8%.(5,6) A 
significant concern when the DOAC medications came into use was the lack of 
reversal agents but these are now in development and becoming available for both 
direct thrombin(7) and factor Xa inhibitors.(8) 
The gastrointestinal (GI) tract is the most common site for major bleeding with 
anticoagulant use.(9,10) There is conflicting data from prospective trials and meta-
analyses of the risk of major GI bleeding with these medications(9,11) and there is 
emerging data from population databases on their longitudinal use. This has not been 
synthesised in the literature to our knowledge, to date. We therefore performed a 
systematic review of the literature and Bayesian network meta-analysis of the risk of 
GI bleeding with the use of DOAC medication compared to warfarin and low molecular 
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weight heparin (LMWH) for all indications. We incorporated observational data and 
addressed limitations of previous, traditional meta-analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Methods 
We followed a pre-specified and peer reviewed PRISMA extension guideline and 
checklist for reporting systematic reviews and network meta-analyses.(12)   
Data Sources and Searches 
Separate electronic database searches were performed on MEDLINE (1946 ± April 
2016) and EMBASE (1947 ± April 2016) for retrospective and prospective studies 
reporting on DOAC with GI bleeding as an outcome. Further searches were conducted 
on The Cochrane Library for systematic reviews and assessment evaluations, the 
National Health Service (UK) Economic Evaluation Database to April 2016 and ISS 
Web of Science to capture conference abstracts and proceedings. The search terms 
XVHG ZHUH ³DSL[DEDQ´ ³HGR[DEDQ´ ³ULYDUR[DEDQ´ ³GDELJDWUDQ´ ³GLUHFW RUDO
DQWLFRDJXODQW´ ³QRYHO RUDO DQWLFRDJXODQW´ DQG ³QRQ-vitamin K antagonist oral 
DQWLFRDJXODQW´.  Medical subject heading (MeSH), free text terms and variations were 
used including the trade names of each medication.  No further limits or language 
restrictions were applied to maximise the yield.  We performed a recursive search of 
the literature by reviewing the bibliographies of the relevant articles identified from the 
search strategy. Two independent reviewers (NB and AC) assessed the eligibility of 
each study for inclusion with any disagreements being resolved by consensus 
decision. We also attempted to contact authors of studies with missing or incomplete 
data to include in our analyses. The search strategy and results are detailed in the 
supplementary appendix.  A data flow diagram is shown in figure 1. 
Prospective or retrospective studies comparing DOAC use with VKA or LMWH for all 
indications, and reporting on GI bleed incidence were eligible for inclusion. We did not 
include studies that compared licensed DOACs against placebo, other oral 
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anticoagulants or antiplatelet medications. After screening relevant titles, we excluded 
studies with no information on the duration of follow up, studies with no comparator 
group, studies with a placebo comparator, studies which only presented adjusted or 
corrected results and studies using an unlicensed DOAC medication. 
Data extraction and quality assessment 
Two researchers (NB & KL) independently extracted data on study design, study 
populations, indication for anticoagulation, dose and duration of medications, and the 
type and definition of GI bleeding. Our study outcomes were:  
Primary outcome 
x Major GI bleeding, defined as a fall in haemoglobin level of 20g/L (1.24 
mmol/L) or more, or leading to transfusion of two or more units of whole 
blood or red cells according to International Society on Thrombosis and 
Haemostasis (ISTH) criteria(13) for RCTs and International 
Classification of Diseases, 9th revision codes (ICD-9) for major GI 
bleeding for observational studies.  
Secondary outcome 
x All GI bleeding, defined as the total number of GI bleeds reported in each 
study. This included major, clinically relevant non-major bleeding 
(CRNM) and minor bleeding events combined or the total number of GI 
bleeding events where there were no details given on the severity of 
bleeding. Studies where bleed location was not reported for all patients 
were excluded from this analysis. 
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We excluded oropharyngeal bleeding and separated upper and lower GI bleeding. 
Data was compared for accuracy and any disagreements were resolved by consensus 
decision. The quality of the studies was assessed by the JADAD score(14) for 
prospective RCTs and the Newcastle-Ottawa scale (NOS) for case-control and cohort 
studies.(15)  
Data synthesis and analysis 
We produced a pooled incidence rate ratio (IRR) of the number of major GI bleeds per 
patient year exposed to each medication. We performed a series of sensitivity 
analyses to test the robustness of the primary hypothesis. We compared study design 
(RCT vs. observational), indication for DOAC use, the dose of DOAC used 
(prophylactic vs. therapeutic) and separated out studies which used bridging therapy 
with either a higher dose of DOAC or LMWH as this may alter the bleeding risk. To 
account for potential differences in patient groups, medication regimes and patients 
characteristics in different geographical populations we excluded studies from North 
America and then studies from Asia and repeated the primary analyses. We performed 
an indirect comparison of each specific medication instead of grouping them by class. 
We also repeated analysis for studies reporting on all GI bleeding events. 
Bayesian network meta-analysis is an increasingly popular method for indirect 
analysis. It performs multiples of pairwise analyses across a range of treatments 
based on direct and indirect evidence. Even when the direct evidence appears 
conclusive the network analysis can produce a more precise level of treatment 
effect.(16) We performed a Bayesian random effects (chosen a priori) regression 
model with vague priors for heterogeneity variances as a conservative approach.(17) 
A further analysis using informative priors was performed as a sensitivity test.(18) We 
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produced an evidence network of drug class with results grouped for; thrombin 
inhibitors (dabigatran), factor Xa inhibitors, warfarin and LMWH. We used adjusted 
continuity corrections of 0.5 to account for studies with no events.(19) To estimate the 
effect of DOAC on the risk of GI bleed we calculated IRR, with 95% credible intervals, 
based on the number of patient years exposed to the medication. The credible interval 
(CrI) is a Bayesian analog of the 95% confidence interval used in traditional meta-
analyses(20). We used the Markov Chain Monte Carlo method(21) to obtain pooled 
effect sizes, considering the result statistically significant if it did not include the value 
1. The relative effects of each medication were converted to a probability that one of 
the specific treatments caused less GI bleeds, and then ranked the medications in 
RUGHUZLWK³EHVW´WR³ZRUVW´ creating a league table.  
Inconsistency test 
Inconsistency in network meta-analysis can be viewed as an extension to 
heterogeneity across studies using different comparisons(22) and refers to the 
variability in the effect size caused by differences in characteristics and effect modifiers 
from study to study. (22,23) A test for inconsistency is important in network meta-
analysis as it estimates the discrepancy between the direct and indirect evidence(24) 
We produced an inconsistency plot and repeated the primary analysis after removing 
outlier studies to assess the robustness of our results. 
All analyses were performed using WinBUGS software (MRC Biostatistics unit)(25) 
using the visual basics applications tool NetMetaXL.(23) 
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Results 
The results from the literature search and fate of articles screened for inclusion are 
shown in figure 1. We included 38 articles (25 RCTs(26±50) and 13 observational 
studies in our analyses(51±63), reporting on 501, 224 patients exposed to 418, 446 
years of anticoagulant medication. The key characteristics of each study and the 
extracted data used in the analyses are displayed in the supplementary material 
(supplementary tables 1 & 2).  The overall quality of the included studies was high with 
all RCTs having a JADAD score of five and all observational studies having a NOS of 
>six (supplementary table 3).  
We contacted 20 authors of relevant articles, of which six replied, but they were unable 
to provide any additional study data.  
Major GI bleeding 
The evidence network for the primary analysis (figure 2) included 31 studies (25 
RCTs(26±50) and six observational studies(52,55±58,62)) reporting on 287, 692 
patients exposed to 230, 090  years of anticoagulant medication. We were unable to 
separate out upper and lower GI bleeds as most of the studies did not include this 
information. On indirect comparison of all of the anticoagulant medications there was 
no difference in the IRR of major GI bleeds (figure 3).  We ranked the anticoagulants 
in order of the IRR of major GI bleed in a league table (table 1. A). Factor Xa inhibitors 
are in the top left position as it has the lowest IRR of causing a major GI bleeding and 
dabigatran is in the bottom right as it has the highest, bearing in mind that these results 
did not reach statistical significance on indirect comparison.  
Inconsistency plot and sensitivity analyses 
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We performed an inconsistency plot to examine discrepancy between direct and 
indirect evidence from our network (supplementary figure 1). There were two outlying 
studies(32,55). These studies were removed from the network and the primary 
outcome analysis was repeated. There was no change in the overall effect, or indeed 
change in the order and ranking in the league table.  
We performed a series of subgroup analyses as sensitivity tests of the primary 
outcome (table 2). There was no change in the effect estimate when removing 
observational studies, analysing according to the indication for anticoagulation, 
examining therapeutic anticoagulation only and when removing studies which using a 
higher dose of DOAC or LMWH as bridging therapy. We excluded studies from North 
America and Asia in turn from the primary analysis and there was no change in the 
associations. We also stratified each medication separately in a further sensitivity 
analysis to examine for a class effect (supplementary figure 2). This network analysis 
showed that edoxaban had a significant reduction in major GI bleeding when 
compared to dabigatran (IRR 0.15, 95% CrI, 0.02 ± 0.66). 
All GI bleeding 
Thirteen studies (4 RCTs(34,45,47,49) and nine observational studies(51,53,54,58±
63)) reporting on 220, 997 patients exposed to 191, 117 years of anticoagulant 
medication were included in the analysis. We found a significant difference in the risk 
of all GI bleeding when comparing factor Xa inhibitors and warfarin (IRR 0.25, 95% Cr 
0.07 ± 0.76) and factor Xa inhibitors with dabigatran (IRR 0.24, 95% CrI 0.07 ± 0.77). 
There was no significant difference with all GI bleeding events between factor Xa 
inhibitors and LMWH (IRR 0.63, 95% CrI 0.10 ± 3.41). There was no significant 
difference in risk seen with the indirect comparisons between dabigatran, warfarin, and 
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LMWH (figure 4). As for major GI bleeds we arranged the treatments in order of the 
greatest impact on all GI bleeding creating a league table (table 1. B.). The ranking 
produced the same order as the primary outcome of major GI bleeding, showing that 
factor Xa inhibitors had the least effect, in the top left of the table, with dabigatran 
having the greatest. The only results that reached statistical significance were for 
direct factor Xa antagonists versus both dabigatran and warfarin.  
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Discussion 
We have shown that there is no increase in major GI bleeding when comparing DOACs 
to warfarin and LMWH for each indication for anticoagulation. The result for major GI 
bleeding was sustained when comparing clinical trial data and data from observational 
studies. When examining the data on all GI bleeding we found a reduced risk of GI 
bleeding with the use of factor Xa inhibitors compared to both warfarin and dabigatran. 
It is important to note that there were only 13 studies in this analysis as we were unable 
to include studies that did not report on bleeding location for clinically relevant non-
major or minor bleeding events. There are plausible hypotheses for these potential 
associations. Excess bleeding risk with warfarin could be due to variations in drug 
levels and subsequent international normalised ratio (INR), reflecting anticoagulant 
effect, which are seen with this medication. Increases in INR can potentiate bleeding 
from the GI mucosa which resolves when warfarin is withdrawn or reversed with the 
addition of vitamin K or prothrombin complexes. Dabigatran is administered as a pro-
drug (dabigatran etexilate) that is activated through absorption through the GI 
mucosa.(64) Non-bleeding GI side effects with the use of dabigatran were reported in 
16.9% of patients in a follow up analysis of a prospective randomised trial.(65) 
Oesophageal mucosal injury is also being seen with dabigatran treatment.(66) 
Oesophagitis can predispose to minor GI bleeding especially in anticoagulated 
patients.(67) This potential effect should be considered by clinicians prescribing these 
medications and thorough documentation of GI side effects should be recorded in 
future studies on anticoagulants. 
In a further sensitivity analysis, analysing each individual DOAC, edoxaban was 
associated with a significant reduction in the risk of major GI bleeding compared to 
dabigatran (figure s3). We cannot account for the difference in association seen with 
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edoxaban compared to the other factor Xa antagonists rivaroxaban and apixaban. 
Possible explanations could be that the difference is due to unaccounted 
heterogeneity between the studies or that there are different pharmacokinetics and 
anticoagulant effects with the different drugs. More corroborative evidence should be 
sought before drawing definitive conclusions. 
Comparison with previous research 
A potential increased risk of GI bleeding was reported in 2013 by Holster et al(68) with 
an increase in the odds (OR 1.58, 95% CI 1.29 - 1.93) when comparing DOAC to all 
other medications. This study also reported an increase in the odds of GI bleeding with 
rivaroxaban (OR 1.48, 95% CI 1.21 - 1.82). This was a standard, pairwise meta-
analysis which only included prospective randomised controlled trials, included some 
placebo controlled studies, did not include observational studies, and did not perform 
indirect comparisons. They also did not account for duration of follow up which is 
important for an outcome such as GI bleeding where longer duration and exposure to 
potential risk may account for increased incidence of bleed. We were able to account 
for duration of exposure by calculating patient years of medication use. We also have 
included more studies, with 30 studies in our primary analysis compared to 17 in this 
earlier study. These reasons may account for our differing results. 
A head to head systematic review and meta-analysis of 23 trials was performed by 
Caldeira et al. in 2015(11). This showed that there was no difference in the major GI 
bleeding rate when comparing DOAC with VKA, LMWH, or acetylsalicylic acid 
separately. In this study all of the DOAC medications were grouped together which 
includes 2 classes of medications namely factor Xa inhibitors and direct thrombin 
inhibitors. We have stratified the different DOACs and also shown no difference in 
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association with the different DOAC classes and a potential significant difference 
between factor Xa inhibitors and dabigatran in studies examining all GI bleeding.  
There is ongoing work on the long term effects of DOAC medications and the results 
of the ORBIT-AF registry(69) and ORANGE study(70) are expected in the near future. 
These large-scale, population based observational studies will give further information 
on the use of these medications outside of controlled clinical trials.  
Strengths  
There are several strengths to this study. By combining the available evidence through 
indirect analysis we have been able to report on over half a million patients followed 
up for over 400, 000 years. We also included data from observational studies to obtain 
a real world estimate of the potential risk with these medications. Prospective 
randomised trials often have stringent inclusion and exclusion criteria which can limit 
their applicability. Importantly, patients with prior GI bleeding are excluded which 
means that the pre-selected cohort are likely to have a much lower GI bleeding risk 
than the general population. Time exposure is an important consideration when 
considering outcomes using anticoagulant medication as these medications are often 
prescribed for many years. We controlled for time exposure by using the IRR as the 
risk estimate in our analyses. Observational studies tend to give data covering a longer 
period of time which is especially important when reporting on rare events such as GI 
bleeding. This data has not been previously included in direct meta-analyses 
investigating the safety of these medications.  
Limitations 
It is important to consider that the different study patients may have different GI 
bleeding risks, depending on the indication for anticoagulation. There are likely to be 
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different, important characteristics between patients for each indication including age, 
co-morbidity, renal function and concomitant medication use. To try and account for 
these differences we performed pre-planned sensitivity analyses of the different 
indications for DOAC therapy (table 3). Unfortunately, due to a paucity of available 
data, we were unable to produce results for some of the comparisons. There are 
various treatment doses of the DOACs available and different dosing regimens used 
worldwide. We did not account for the different doses of medications here as it would 
have markedly extended the data network and also reduced the sample size in each 
treatment arm. This could have some bearing as bleeding risk increases with higher 
doses(71). We performed a subgroup analysis of therapeutic and prophylactic doses 
of DOAC (table 3) and found no change in the association with no significant 
differences between the medication classes. To account for potential variation in 
dosing or patient characteristics seen in different countries we performed subgroup 
analyses after excluding patients from North America and then Asia in turn. Again 
there was no change in the overall effect estimates. Whilst higher doses of each 
individual medication may pose additional major GI bleeding ULVNZHKDYHQ¶Wfound a 
difference in the association at prophylactic or therapeutic doses. 
The definitions of GI bleeding were not consistent between all of the studies identified 
from our search. This is a potential bias with meta-analyses as there is a danger of 
comparing different clinical outcomes. To account for this potential effect we used strict 
definitions of major GI bleeding for our primary analysis, namely ISTH criteria for 
randomised trials and ICD-9 admission codes for the observational studies. The ICD-
9 codes have been validated for anticoagulant associated GI bleeding and have >90% 
sensitivity and >83% specificity for any GI bleeding and major GI bleeding.(72)  
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We have not been able to differentiate between upper and lower GI bleeds in our 
network meta-analysis because this detail was not available for most of the included 
studies. This data should be captured in future studies. There is ongoing research 
from anticoagulant registries which will hopefully report on the specific bleed 
locations.(73) Concomitant use of medications such as non-steroidal anti-
inflammatory medications and antiplatelets can increase the GI bleeding risk (74) and 
gastroprotective medications such as proton pump inhibitors may reduce the bleeding 
risk. We were unable to investigate these potential effects in this study although we 
would not expect there to be a differential effect for each class of anticoagulant.  
Implications for clinical practice 
The DOACs are increasingly being used, largely due to the lack of dose adjustments 
and drug level monitoring which is required with traditional medications. Although 
warfarin therapy has been widely used and effective for over 60 years it requires 
UHJXODUWKHUDSHXWLFPRQLWRULQJ3UHYLRXVZRUNKDVVKRZQWKDWWKH³WLPHLQWKHUDSHXWLF
ranJH´IRUwarfarin patients is only 50 to 70%(75) which makes DOAC medications an 
attractive alternative.   
Clinicians withhold anticoagulants due to a perceived bleeding risk but those at higher 
risk for bleeding are also those at highest risk for thromboembolic events due to their 
co-morbidities.(76) In patients with higher bleeding risk a common occurrence is for 
aspirin to be prescribed instead of warfarin due to a perceived lower risk of bleeding. 
A study in 2007 showed no significant difference in major bleeding between warfarin 
and aspirin in patients >75 years with AF.(77) We are now reporting no difference in 
major GI bleeding between DOAC medications and warfarin.  
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GI bleeding remains a serious side effect of anticoagulant use. DOACs are already 
used by a large numbers of patients and as expected adherence to guidelines 
continues this use could increase exponentially. It is therefore important to have robust 
data on the risk profiles of these medications. In this study we found no difference in 
the risk of major GI bleeding when comparing DOAC, warfarin and LMWH 
anticoagulation medications which supports their use for a range of anticoagulant 
indications. We have shown a potential association with a decreased risk of all GI 
bleeding events with the use of factor Xa inhibitors when compared to warfarin and 
direct thrombin inhibitors. Further work is needed but this may help with clinical 
decisions when selecting an anticoagulant. 
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